Medicare AdvantagePrior AuthHigh impact
Hyrnuo (sevabertinib)
Humana·Oncology·Medicare Advantage
We identified it
Jul 1, 2026
Summary
Unable to complete analysis. The policy document is a 'Summary Only' with no accessible content details provided. The source URL references a Humana internal system (DCTM) that contains the actual Prior Authorization policy for Hyrnuo (sevabertinib), but the policy content itself was not included in this request. To provide actionable guidance, the billing team needs the full policy document including coverage criteria, prior authorization requirements, affected diagnosis codes, and effective date.
Action Required
URGENT - By end of business today: (1) Billing team must obtain and review the complete Hyrnuo (sevabertinib) policy document from the Humana source URL (https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a56a616). (2) Extract specific prior authorization requirements, covered indications, billing/HCPCS codes, and effective date. (3) Notify providers and front desk staff of any new prior authorization workflows. (4) Update billing system rules to require prior auth for this medication if applicable. Without the full policy content, billing teams risk processing claims without required authorizations, resulting in denials. Contact Humana account representative if access is restricted.